HomepageIPN • EPA
add
Ipsen
Vorige slotkoers
€ 162,60
Dag-range
€ 160,30 - € 163,40
Jaar-range
€ 87,95 - € 170,80
Beurswaarde
13,63Â mld. EUR
Gem. volume
114,91K
Koers/winst
30,42
Dividendrendement
-
Primaire beurs
EPA
Marktnieuws
NDAQ
0,29%
1,68%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 996,05Â mln. | 9,29% |
Bedrijfskosten | 523,20Â mln. | 14,20% |
Netto inkomsten | 54,75Â mln. | -3,86% |
Netto winstmarge | 5,50 | -12,00% |
Winst per aandeel | — | — |
EBITDA | 331,25Â mln. | 1,04% |
Effectief belastingtarief | 28,80% | — |
Balans
Totale activa
Totale passiva
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,53Â mld. | 124,75% |
Totale activa | 6,94Â mld. | 7,75% |
Totale passiva | 2,60Â mld. | 15,23% |
Totaal aandelenvermogen | 4,34 mld. | — |
Uitstaande aandelen | 82,63 mln. | — |
Koers-boekwaardeverhouding | 3,10 | — |
Rendement op activa | 9,37% | — |
Rendement op kapitaal | 12,24% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 54,75Â mln. | -3,86% |
Operationele kasstroom | 305,85Â mln. | 36,08% |
Kasstroom uit beleggingen | -241,15Â mln. | -78,37% |
Kasstroom uit financiering | -28,15Â mln. | -607,21% |
Nettomutatie in liquide middelen | 39,35Â mln. | -62,54% |
Vrije kasstroom | 172,09Â mln. | 24,63% |
Over
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
CEO
Opgericht
1929
Website
Werknemers
5.535